J Infect Dis. 1995 May;171(5):1166-71.

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.

van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al.

Source

Department of Internal Medicine (Clinical AIDS Unit), University of Amsterdam, Academic Medical Centre, Netherlands.

Abstract

In a phase I/II study, 7 levels of 3TC therapy (from 0.5 to 20.0 mg/kg/day) were studied in 104 asymptomatic and mildly symptomatic human immunodeficiency virus-infected patients with CD4 cell counts < or = 400 x 10(6)/L. Mild and transient episodes of diarrhea, headache, fatigue, nausea, and abdominal pain were the most frequent events reported. No dose-limiting toxicities were observed. Small and transient increases in CD4 cell counts were detected during the first 4 weeks of treatment. These were followed by progressive declines during prolonged therapy. Sustained decreases in beta 2-microglobulin, neopterin, and p24 antigen levels were seen over the 52-week study. There was no consistent dose-response correlation for any surrogate marker. Penetration of 3TC into cerebrospinal fluid (CSF) was in the same range as reported for ddC and ddI; the mean CSF-to-serum ratio was 0.06. These findings indicate that 3TC exhibits an excellent safety profile and has antiretroviral activity at the dosages studied.

PMID:: 7751691; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Related citations

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. [Ann Intern Med. 1996]
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL, Rubin M. Ann Intern Med. 1996 Aug 1; 125(3):161-72.
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. [J Infect Dis. 1995]
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, Hirst HM, Vicary CA, Quinn JB. J Infect Dis. 1995 Jun; 171(6):1438-47.
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. [J Infect Dis. 1996]
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, Rubin M, Yuen G, Mueller B, Sloas M, et al. J Infect Dis. 1996 Jul; 174(1):16-25.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection. [Drugs. 2003]
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.
Review Studies of zidovudine in combination with didanosine and zalcitabine. [J Acquir Immune Defic Syndr Hum Retrovirol....]
Review Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 1:S52-6.

See reviews... See all...

Cited by 12 PubMed Central articles

Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. [Antimicrob Agents Chemother. 2004]
Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.
Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, Hoelscher DD. Antimicrob Agents Chemother. 2004 Jan; 48(1):176-82.
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. [Antimicrob Agents Chemother. 2002]
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks CB. Antimicrob Agents Chemother. 2002 Aug; 46(8):2387-92.
Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. [J Virol. 2000]
Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.
Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. J Virol. 2000 Jul; 74(14):6262-8.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptoma...
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
J Infect Dis. 1995 May ;171(5):1166-71.

PubMed
The ultrastructural morphology of air embolism: platelet adhesion to the interfa...
The ultrastructural morphology of air embolism: platelet adhesion to the interface and endothelial damage.
Br J Exp Pathol. 1973 Apr ;54(2):163-72.

PubMed
HIV risk behaviors and obstacles to condom use among Puerto Rican men in New Yor...
HIV risk behaviors and obstacles to condom use among Puerto Rican men in New York City who have sex with men.
Am J Public Health. 1996 Nov ;86(11):1619-22.

PubMed
Pulmonary complications of human immunodeficiency virus infection in Bujumbura, ...
Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi.
Am Rev Respir Dis. 1993 Mar ;147(3):658-63.

PubMed
Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in ra...
Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
Biochem Pharmacol. 1997 Apr 25 ;53(8):1187-95.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Related citations

Cited by 12 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information